Table 3.
LncRNAs role in immunity related disease.
| LncRNA | Model | Pathology | Main Results | References |
|---|---|---|---|---|
| ANRIL | Aortic soy muscle cells/cardiovascular in vitro models | Coronary artery disease Type 2 diabetes Intercranial aneurisms |
Associated with susceptibility to cardiovascular disorder | [114] |
| BANCR | Different melanoma cell lines mice xenografts |
Melanoma | Associated with proliferation, malignancy and prognosis of melanoma via MAPK pathway | [115,116] |
| FAS-AS1 | Lymphoma cell lines | Autoimmune diseases Lymphoma |
Found downregulated in lymphoma cells is involved in sFAS regulation and alternative splicing | [117] |
| HOXD-AS1 | Neuroblastoma cell lines | Neuroblastoma | Marker of neuroblastoma progression and malignancy | [118] |
| HOTAIR | Synoviocytes | Synovial inflammation Osteoarthritis |
Downregulation reduces inflammation and osteoarthritis via Wnt/β-catenin pathway | [119] |
| Lnc13 | Human intestinal sections and cells, macrophages |
Celiac disease (CeD) | Associated with a wide panel of genes involved in inflammation in CeD | [120,121] |
| Linc-Maf-4 | Patient macrophages | Multiple sclerosis | Associated with the pathogenesis and the severity of multiple sclerosis | [122] |
| LncRNA-CMPK2 | Human cell lines | HCV infection | Correlated with HCV infection via | [123] |
| lncRNADQ786243 | Chron’s disease patients | Chron’s disease | Correlated with Chron’s disease development via FOXP3 | [16] |
| LncRNA-p21 | Rheumatoid arthritis patients’ T cells | Rheumatoid arthritis | Upregulated in response to Metotrexate to control the pathology | [124] |
| lncRNA RMPR | Cartilage-hair hypoplasia patients | Cartilage-hair hypoplasia | Mutations associated with autoimmune pathologies in joints and kidneys and hematological abnormalities | [98,106,107,125] |
| lncRNA SAS-ZFAT | Autoimmune thyroid disease patients | Autoimmune thyroid disease(AITD) | Increases susceptibility to AITD | [126] |
| MALAT1 | HREC cells | Diabetic retinopathy | Correlated to significant increases of his levels and associated inflammatory transcripts | [127] |
| MORRBID | Hypereosinophilic syndrome patients and myeloid cells | Hypereosinophilic syndrome | Potential therapeutic target for inflammatory disorders characterized by short-lived aberrant myeloid cell duration. | [82] |
| NRIR | Systemic sclerosis | Systemic sclerosis | Upregulated together with INF response in SSc patients | [82] |
| OLA1P2 | Colorectal cancer patients | Colorectal patients | Correlated with the progression of the tumor and to poor prognosis | [128] |